News

Categories

October 23, 2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

October 23, 2026

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

October 19, 2026

Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

October 15, 2026

Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

October 2, 2026

Zymeworks to Present on Preclinical and Clinical Programs at Multiple Upcoming Medical Conferences

September 28, 2026

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

September 23, 2026

Zymeworks Completes Acquisition of Theravance Biopharma

August 31, 2026

Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA

August 25, 2026

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

August 11, 2026

Zymeworks Announces Participation in Upcoming Investor Conferences

August 6, 2026

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

July 16, 2026

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026